4 results on '"Matsukawa R"'
Search Results
2. Central neuregulin-1/ErbB signaling modulates cardiac function via sympathetic activity in pressure overload-induced heart failure.
- Author
-
Matsukawa R, Hirooka Y, Ito K, Honda N, and Sunagawa K
- Subjects
- Animals, Aorta, Abdominal physiopathology, Blood Pressure, Brain Stem metabolism, Heart physiopathology, Hemodynamics, Hypertrophy, Left Ventricular, Male, Norepinephrine urine, Rats, Rats, Inbred WKY, Signal Transduction, Sympathetic Nervous System, Time Factors, Ventricular Dysfunction, Left physiopathology, Heart Failure physiopathology, Neuregulin-1 metabolism, Oncogene Proteins v-erbB metabolism
- Abstract
Objectives: Neuregulin-1 (NRG-1)/ErbB signaling in the heart is reported to have a crucial role in heart failure. We recently demonstrated that NRG-1 signaling has sympathoinhibitory effects in the brain cardiovascular control center. How this central signaling impacts sympathoexcitation in heart failure, however, is unknown. Here we examined the role of central NRG-1/ErbB signaling in modulating the sympathetic nervous system in pressure overload-induced heart failure., Methods and Results: Pressure overload-induced heart failure was induced in Wistar-Kyoto rats by banding the abdominal aorta. Rats were followed up for 15 weeks. Compared to sham-operated rats, aortic-banded rats showed left ventricle (LV) hypertrophy, LV dilation, and LV dysfunction [reducing fractional shortening (%fractional shortening), increased LV end-diastolic pressure, decreased positive and negative pressure differential (±dp/dt(max))], and increased urinary norepinephrine excretion. Aortic banding led to reduced expression of NRG-1 in the brainstem at 10 weeks after banding and reduced expression of ErbB2 at 5 weeks, but did not affect ErbB4. Central administration of recombinant NRG-1β at 5 weeks for 2 weeks attenuated LV hypertrophy, improved LV dilatation, prevented LV dysfunction (improvement of %fractional shortening and ±dp/dt(max), and reduction of LV end-diastolic pressure), and lowered urinary norepinephrine excretion at 10 weeks, and these effects were still observed at 15 weeks., Conclusion: NRG-1/ErbB signaling in the brainstem is impaired during the progression of pressure overload-induced heart failure. Activation of central NRG-1 signaling improves cardiac function through sympathoinhibition. These findings provide a new treatment concept and support the benefit of NRG-1 treatment in heart failure.
- Published
- 2014
- Full Text
- View/download PDF
3. Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure.
- Author
-
Honda N, Hirooka Y, Ito K, Matsukawa R, Shinohara K, Kishi T, Yasukawa K, Utsumi H, and Sunagawa K
- Subjects
- Animals, Heart Failure etiology, Heart Failure mortality, Heart Failure physiopathology, Hypertension complications, Hypertrophy, Left Ventricular etiology, Infusions, Intraventricular, Male, Prognosis, Rats, Rats, Inbred Dahl, Ventricular Dysfunction, Left drug therapy, Ventricular Dysfunction, Left etiology, Ventricular Dysfunction, Left physiopathology, Ventricular Function, Left drug effects, Antihypertensive Agents pharmacology, Heart Failure drug therapy, Hypertension drug therapy, Imidazoles pharmacology
- Abstract
Objectives: Enhanced central sympathetic outflow is an indicator of the prognosis of heart failure. Although the central sympatholytic drug moxonidine is an established therapeutic strategy for hypertension, its benefits for hypertensive heart failure are poorly understood. In the present study, we investigated the effects of central sympathoinhibition by intracerebral infusion of moxonidine on survival in a rat model of hypertensive heart failure and the possible mechanisms involved., Methods and Results: As a model of hypertensive heart failure, we fed Dahl salt-sensitive rats an 8% NaCl diet from 7 weeks of age. Intracerebroventricular (ICV) infusion of moxonidine (moxonidine-ICV-treated group [Mox-ICV]) or vehicle (vehicle-ICV-treated group [Veh-ICV]) was performed at 14-20 weeks of age, during the increased heart failure phase. Survival rates were examined, and sympathetic activity, left ventricular function and remodelling, and brain oxidative stress were measured. Hypertension and left ventricular hypertrophy were established by 13 weeks of age. At around 20 weeks of age, Veh-ICV rats exhibited overt heart failure concomitant with increased urinary norepinephrine (uNE) excretion as an index of sympathetic activity, dilated left ventricle, decreased percentage fractional shortening, and myocardial fibrosis. Survival rates at 21 weeks of age (n = 28) were only 23% in Veh-ICV rats, and 76% (n = 17) in Mox-ICV rats with concomitant decreases in uNE, myocardial fibrosis, collagen type I/III ratio, brain oxidative stress, and suppressed left ventricular dysfunction., Conclusion: Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure. Central sympathoinhibition can be effective for the treatment of hypertensive heart failure.
- Published
- 2013
- Full Text
- View/download PDF
4. Neuregulin-1/ErbB signaling in rostral ventrolateral medulla is involved in blood pressure regulation as an antihypertensive system.
- Author
-
Matsukawa R, Hirooka Y, Nishihara M, Ito K, and Sunagawa K
- Subjects
- Animals, Base Sequence, Heart Rate, Medulla Oblongata physiopathology, RNA, Small Interfering, Rats, Rats, Inbred SHR, Rats, Inbred WKY, Receptors, GABA-A drug effects, Blood Pressure, Genes, erbB, Hypertension physiopathology, Medulla Oblongata metabolism, Neuregulin-1 metabolism, Signal Transduction
- Abstract
Objectives: Neuregulin-1 (NRG-1), located in the central nervous system (CNS), plays an important role in synaptic function, neurite outgrowth, and survival of neurons and glia acting on the ErbB receptor family. However, the functional role of NRG-1/ErbB signaling in the CNS and blood pressure regulation is unknown, particularly in the rostral ventrolateral medulla (RVLM), a major vasomotor center. Thus, we investigated whether NRG-1/ErbB signaling in the RVLM is involved in blood pressure regulation., Methods and Results: Microinjection of NRG-1 into the RVLM decreased arterial blood pressure, heart rate (HR), and renal sympathetic nerve activity (RSNA) in Wistar rats. In contrast, microinjection of an ErbB2 or ErbB4 inhibitor into the RVLM increased arterial pressure, HR, and RSNA. ErbB2 expression levels in the brainstem were significantly lower in spontaneously hypertensive rats (SHRs) than in Wistar-Kyoto (WKY) rats. Depressor responses to NRG-1 and pressor responses to the ErbB2 inhibitor were significantly smaller in SHRs than in WKY rats (P < 0.05). Furthermore, the inhibition of ErbB2 expression in the RVLM by RNA interference significantly increased arterial pressure, HR, and urinary norepinephrine excretion in conscious WKY rats (P < 0.01)., Conclusion: Our findings indicate that the NRG-1/ErbB signaling in the RVLM has depressor and sympathoinhibitory effects. Reduced NRG/ErbB2 signaling in the RVLM may contribute to the neural mechanisms of hypertension.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.